- Pharmacological targeting via AKT, PTEN and TGF-beta pathway integration using novel therapeutics. NHMRC. (D Richardson, S Assinder and Q Dong) 2010-2013
- Efficacy of cPLA2 inhibitor. The University of Sydney Bridge Grant. (Q Dong and P Witting), 2010,
- Relationship between Arachidonic Acid and Protein Kinase B Signalling Pathways in Prostate Australian Urological Foundation Research Grants (P Sved), 2010 $30,000
- Secreted Phospholipase A2 in Prostate Cancer. Cancer Council NSW, (K Scott, Q Dong, G Grahm, P Russell). 2006-2008 $420,000
- University of Sydney Early career Researcher Award (P Sved) 2009
- Donation for prostate cancer research. Reginald Ward and Adrian Cotter Foundation. (Q Dong) 2004-2008, $150,000,
- Sydney Cancer Centre Foundation Research Grant 2006 (P Sved)
- Australian Urological Foundation Research Grant 2006 (P Sved)
- Donation for prostate cancer research. Meriton. (Q Dong) 2003-5, $300,000.
- Development and Support Fellowship, Cancer Institute NSW Career. (Q Dong) 2005-2007, $600,000
- Establishment of technical protocols for isolation of prostate stem cells. The University of Sydney Cancer Fund Grant, (Q Dong). 2006-7, $100,000.
- Oncogenic action and therapeutic potential of PLA2 in prostate cancer NHMRC (Dong, Scott, Graham & Russell), 2004-2006, $490,500
- The role of FHL1 & SPINK1 in androgen independent prostate cancer. New South Wales Cancer Council (Dong & Singh), 2002-2004, $180,000
- Function and regulation of inhibitor of DNA binding-1 in prostate cancer. Cure Cancer Foundation, Australia (Dong & McLeod), 2004, $60,000
- Australian Urological Foundation Research Grants (P Sved, Q Dong), 2004, $25,000
